Good morning :)
Place Order
Add to Watchlist

Valiant Laboratories Ltd

VALIANTLAB

Valiant Laboratories Ltd

VALIANTLAB
Health CarePharmaceuticals
SmallcapWith a market cap of ₹509 cr, stock is ranked 1,851
High RiskStock is 3.02x as volatile as Nifty
119.280.11% (-0.13)
119.280.11% (-0.13)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹509 cr, stock is ranked 1,851
High RiskStock is 3.02x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹509 cr, stock is ranked 1,851
High RiskStock is 3.02x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
-51.112.15
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.906.610.52%

Forecast & Ratings

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Valiant Laboratories Limited specializes in manufacturing pharmaceutical intermediates, particularly paracetamol API.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Loading...

Financial YearFY 2023FY 2024TTM
Total Revenue338.77191.74121.92
Raw Materialssubtract276.76168.67131.43
Power & Fuel Costsubtract7.378.33
Employee Costsubtract4.614.31
Selling & Administrative Expensessubtract3.732.69
Operating & Other expensessubtract6.356.46
Depreciation/Amortizationsubtract1.561.972.06
Interest & Other Itemssubtract0.250.080.10
Taxes & Other Itemssubtract9.14-1.09-1.70
EPS8.910.08-2.29
DPS0.000.000.00
Payout ratio0.000.000.00

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Valiant Laboratories Ltd1,592.312.15
Sun Pharmaceutical Industries Ltd45.106.440.75%
Cipla Ltd29.414.520.87%
Torrent Pharmaceuticals Ltd68.5016.550.84%

Price Comparison

Compare VALIANTLAB with any stock or ETF
Compare VALIANTLAB with any stock or ETF
VALIANTLAB
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Increased Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has increased by 1.71%

Decreased Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has decreased by 1.89%

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding74.94%0.00%0.00%0.00%25.06%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

SepOctDec '23MarJunSep8.64%8.64%7.08%3.48%1.89%0.00%

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

VALIANTLAB has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

Dividends

Hmm, looks like data is unavailable here. Please come back after some time
News & Opinions
Earnings
Valiant Laboratories reports consolidated net loss of Rs 4.74 crore in the September 2024 quarter

Net loss of Valiant Laboratories reported to Rs 4.74 crore in the quarter ended September 2024 as against net profit of Rs 0.79 crore during the previous quarter ended September 2023. Sales declined 63.93% to Rs 21.48 crore in the quarter ended September 2024 as against Rs 59.55 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales21.4859.55 -64 OPM %-31.38-2.33 - PBDT-3.391.55 PL PBT-3.911.06 PL NP-4.740.79 PL Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Corporate
Valiant Laboratories to conduct board meeting

Valiant Laboratories will hold a meeting of the Board of Directors of the Company on 12 November 2024Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Valiant Laboratories reports consolidated net loss of Rs 0.51 crore in the June 2024 quarter

Net loss of Valiant Laboratories reported to Rs 0.51 crore in the quarter ended June 2024 as against net profit of Rs 4.27 crore during the previous quarter ended June 2023. Sales declined 63.28% to Rs 18.88 crore in the quarter ended June 2024 as against Rs 51.41 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales18.8851.41 -63 OPM %-12.617.43 - PBDT0.376.24 -94 PBT-0.165.78 PL NP-0.514.27 PL Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Valiant Laboratories to conduct board meeting

Valiant Laboratories will hold a meeting of the Board of Directors of the Company on 12 August 2024.Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Valiant Laboratories schedules AGM

Valiant Laboratories announced that the 3rd Annual General Meeting (AGM) of the company will be held on 8 August 2024.Powered by Capital Market - Live

4 months agoCapital Market - Live